Finance

Beta
Lists
P8A:SGX
Cordlife Group Ltd
SGD 0.12
0.00%
(0.00) 1D
Jun 2, 8:58:41 AM GMT+8  ·   SGD
All symbols
SymbolPriceChange% Change
Generating top insights for P8A...
Mkt. cap
33.17M
Avg. vol.
3.34K
Volume
0.00
52-wk high
SGD 0.33
52-wk low
SGD 0.12
Shares outstanding
267.53M
No. of employees
111
Mkt. cap
33.17M
Avg. vol.
3.34K
Volume
0.00
52-wk high
SGD 0.33
52-wk low
SGD 0.12
Shares outstanding
267.53M
No. of employees
111
News stories
From sources across the web
Profile
Cordlife Group Limited, is a consumer health company incorporated in May 2001 and a provider of cord blood and cord lining banking services in Asia. Cordlife has been listed on the mainboard of SGX since March 2012. Cordlife Group owns the largest network of cord blood banks in Asia with full stem cell processing and storage facilities in six markets including Singapore, Hong Kong, India, Indonesia, and the Philippines. Beyond cord blood and cord lining banking, Cordlife offers diagnostics services, particularly for the mother and child segment, including urine-based newborn metabolic screening, non-invasive prenatal testing, paediatric vision screening and family genetic screening services. Cordlife's stem cell processing and storage facilities in Singapore, Hong Kong, India, Indonesia, the Philippines and Malaysia were accredited by AABB until 2024 when its accreditation was withdrawn. In November 2023, the Ministry of Health of Singapore revealed that Cordlife Group had exposed cryopreserved cord blood units at suboptimal temperatures, damaging the cord blood units belonging to at least 2,150 clients and rendering them unsuitable for stem cell transplant purposes. Wikipedia
About Cordlife Group Ltd
CEOYiu Pang Fai
Employees111
FoundedMay 2, 2001
Headquarters-
SectorHealth care provider
Websitecordlife.com
Previous reportsAll values in SGD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in SGD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
9.59M
10.21M
9.46M
8.99M
Cost of goods sold
4.12M
4.16M
4.05M
3.78M
Cost of revenue
4.12M
4.16M
4.05M
3.78M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.78M
9.42M
10.52M
7.60M
Operating expense
8.61M
9.29M
10.41M
7.47M
Total operating expenses
12.73M
13.45M
14.46M
11.25M
Operating income
-3.14M
-3.24M
-5.00M
-2.26M
Other non operating income
-
-
-
565.00K
EBT including unusual items
-2.18M
-2.33M
-4.30M
-1.70M
EBT excluding unusual items
-2.18M
-2.33M
-4.38M
-1.70M
Income tax expense
116.50K
149.00K
1.26M
19.00K
Effective tax rate
-5.33%
-6.39%
-29.22%
-1.12%
Other operating expenses
-170.50K
-133.00K
-111.00K
-132.00K
Net income
-2.30M
-2.48M
-5.55M
-1.72M
Net profit margin
-24.00%
-24.32%
-58.72%
-19.13%
Earnings per share
-
-
-
-
Interest and investment income
743.50K
642.00K
589.00K
-
Interest expense
-45.50K
-27.00K
-34.00K
-28.00K
Net interest expenses
698.00K
615.00K
555.00K
-28.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-2.03M
-2.17M
-4.29M
-1.33M
Gain or loss from assets sale
1.50K
1.00K
220.00K
5.00K
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer